Bayer builds on NAT (nucleic acid diagnostic) with $61.4 million Visible Genetics deal
This article was originally published in Clinica
Bayer Diagnostics is to significantly expand its nucleic acid diagnostic (NAT) business with its planned $61.4m acquisition of tiny pharmacogenomics company Visible Genetics. In the cash deal, Bayer is offering $1.50 per Visible Genetics' share and its series A preferred shares at par plus accrued dividends.
You may also be interested in...
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.